ClinicalTrials.gg
CompletedNCT01288443Updated Sep 24, 2015Results posted

Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy

A Phase 2 interventional study of Alirocumab and Placebo (for alirocumab) in Hypercholesterolemia, sponsored by Sanofi. Completed at 38 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-09-24.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
183
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.

Enrollment
19th of 43
183 · median 107
Started
2011
with 6 others
Phase 2
9 of 43
none open now
Registered
3rd of 43
by date
Lead sponsor
28 of 43
Sanofi

Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 19th largest by enrollment, is one of 7 that started in 2011, is one of 9 in phase 2, and was the 3rd registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About alirocumab

alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing alirocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

Primary Objective:

  • To evaluate the effect of alirocumab (SAR236553/REGN727) on low-density lipoprotein cholesterol (LDL-C) levels after 12 weeks of treatment in comparison with placebo in participants with LDL-C ≥ 100 mg/dL (≥ 2.59 mmol/L) on ongoing stable atorvastatin therapy.

Secondary Objectives:

  • To evaluate the effects of alirocumab on other lipid levels after 12 weeks of treatment in comparison with placebo
  • To evaluate the safety and tolerability of alirocumab
  • To evaluate the development of anti-alirocumab antibodies
  • To evaluate the pharmacokinetics of alirocumab
Read the detailed description

The duration of study participation depended on the status of the participant at screening:

  • For participants receiving atorvastatin 10 mg, 20 mg, or 40 mg at a stable dose for at least 6 weeks prior to screening, the study participation was to be approximately 21 weeks including a screening period of 1 week, a double-blind treatment period of 12 weeks and a follow-up period of 8 weeks.
  • For participants receiving a lipid-lowering treatment other than atorvastatin or not at stable dose of atorvastatin 10 mg, 20 mg, or 40 mg for at least 6 weeks prior to screening, or drug naive participants, the study participation was to be approximately 27 weeks including a screening period of 1 week, a run-in treatment period with atorvastatin 10 mg, 20 mg, or 40 mg at a stable dose of 6 weeks, a double-blind treatment period of 12 weeks, and a follow-up period of 8 weeks.
03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with primary hypercholesterolemia receiving a lipid-lowering treatment other than atorvastatin or not at stable dose of atorvastatin 10 mg, 20 mg, or 40 mg for at least 6 weeks prior to screening period or drug naive participants if they are likely to have low-density lipoprotein cholesterol (LDL-C) ≥ 100 mg/dL (≥ 2.59 mmol/L) at the end of the 6-week run-in treatment period on atorvastatin therapy

OR

  • Participants with primary hypercholesterolemia treated with atorvastatin at stable dose of 10 mg, 20 mg, or 40 mg for at least 6 weeks prior to screening period and likely to have LDL-C ≥ 100 mg/dL (≥ 2.59 mmol/L) at the screening visit

Exclusion criteria

Exclusion criteria:

  1. LDL-C \< 100 mg/dL (\< 2.59 mmol/L):

    • After the run-in period on atorvastatin (10 mg, 20 mg, or 40 mg) for participants receiving a lipid-lowering treatment other than atorvastatin or not at stable dose of atorvastatin 10 mg, 20 mg, or 40 mg for at least 6 weeks prior to the screening, or drug naive participant

    OR

    • At the first visit for participants who were being treated with stable dose of atorvastatin (10 mg, 20 mg, or 40 mg) for at least 6 weeks prior to screening
  2. Participants not previously instructed on a cholesterol-lowering diet
  3. Participants with type 1 diabetes
  4. Participants with type 2 diabetes treated with insulin
  5. Participants with type 2 diabetes and with an (HbA1c) ≥ 8.5% at screening visit (considered poorly controlled)
  6. Laboratory findings measured before randomization:

    • Triglycerides (TG) > 350 mg/dL (> 3.95 mmol/L) at screening visit
    • Positive serum or urine pregnancy test in females of
  7. Pregnant or breast-feeding women
  8. Women of childbearing potential with no effective method

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
183 participants (actual)

Study arms

  • Placebo comparator
    Placebo Q2W

    Placebo (for alirocumab) every 2 weeks (Q2W) for 12-weeks in combination with atorvastatin stable dose.

    Drug: Placebo (for alirocumab) · Drug: Atorvastatin

  • Experimental
    Alirocumab 50 mg Q2W

    Alirocumab 50 mg Q2W for 12-weeks in combination with atorvastatin stable dose.

    Drug: Alirocumab · Drug: Atorvastatin

  • Experimental
    Alirocumab 100 mg Q2W

    Alirocumab 100 mg Q2W for 12-weeks in combination with atorvastatin stable dose.

    Drug: Alirocumab · Drug: Atorvastatin

  • Experimental
    Alirocumab 150 mg Q2W

    Alirocumab 150 mg Q2W for 12-weeks in combination with atorvastatin stable dose.

    Drug: Alirocumab · Drug: Atorvastatin

  • Experimental
    Alirocumab 200 mg Q4W

    Alirocumab 200 mg every 4 weeks (Q4W) and alternating placebo Q2W for 12-weeks in combination with atorvastatin stable dose.

    Drug: Alirocumab · Drug: Placebo (for alirocumab) · Drug: Atorvastatin

  • Experimental
    Alirocumab 300 mg Q4W

    Alirocumab 300 mg Q4W and alternating placebo Q2W for 12-weeks in combination with atorvastatin stable dose.

    Drug: Alirocumab · Drug: Placebo (for alirocumab) · Drug: Atorvastatin

Interventions

  • Two SC injections in the abdomen only.

    Also known as: SAR236553, REGN727

  • DrugPlacebo (for alirocumab)

    Two subcutaneous (SC) injections in the abdomen only.

  • Orally once daily at a stable dose of 10 mg, 20 mg, or 40 mg as background therapy.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis

    Calculated LDL-C values were obtained using the Friedewald formula. Baseline adjusted least squares (LS) means and standard errors were estimated using an analysis of covariance (ANCOVA) model including available post-baseline data on treatment from first study drug injection up to 21 days after last study drug injection (on-treatment analysis). Missing Week 12 data were imputed by last observation carried forward \[LOCF\] method.

    Time frame: Baseline to Week 12 (LOCF)

Secondary outcomes

  1. Absolute Change From Baseline in Calculated LDL-C (mmol/L) at Week 12 - On-Treatment Analysis

    Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

    Time frame: Baseline to Week 12 (LOCF)

  2. Absolute Change From Baseline in Calculated LDL-C (mg/dL) at Week 12 - On-Treatment Analysis

    Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

    Time frame: Baseline to Week 12 (LOCF)

  3. Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) and <70 mg/dL (1.81 mmol/L) at Week 12 - On-Treatment Analysis

    Time frame: Week 12 (LOCF)

  4. Percent Change From Baseline in Total Cholesterol, High-density Lipoprotein Cholesterol (HDL-C), Non-HDL-C and Apolipoprotein B (Apo-B) at Week 12 - On-Treatment Analysis

    Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

    Time frame: Baseline to Week 12 (LOCF)

  5. Percent Change From Baseline in Fasting Triglycerides and Lipoprotein(a) at Week 12 - On-Treatment Analysis

    Since the assumptions of normal distribution and equality of variances were not verified for the lipid parameters, percent changes were expressed as median (inter-quartile range).

    Time frame: Baseline to Week 12 (LOCF)

  6. Absolute Change in the Ratio Apolipoprotein B/Apolipoprotein A-1 (ApoB/ApoA-1) From Baseline to Week 12 - On-Treatment Analysis

    Adjusted LS mean and standard errors were estimated using the same ANCOVA as for primary endpoint.

    Time frame: Baseline to Week 12 (LOCF)

07

Results

Posted Sep 24, 2015

Participant flow

The study was conducted at 38 centers in the United States of America. Overall, 514 participants were screened between January 2011 and August 2011, 331 of whom were screen failures and screen failures were mainly due to exclusion criteria met.

Participant flow — Overall Study
MilestonePlaceboAlirocumab 50 mg Q2WAlirocumab 100 mg Q2WAlirocumab 150 mg Q2WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4W
Started313031313030
Treated313031312930
Completed312930272325
Not completed011475
Withdrew: Adverse event001131
Withdrew: Poor compliance to protocol000001
Withdrew: Participant moved000121
Withdrew: Consent withdrawn by participant000001
Withdrew: Lost to follow-up010000
Withdrew: Study drug auto-injector administration000011
Withdrew: Other than above000210

Outcome measures

PrimaryPercent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis

Calculated LDL-C values were obtained using the Friedewald formula. Baseline adjusted least squares (LS) means and standard errors were estimated using an analysis of covariance (ANCOVA) model including available post-baseline data on treatment from first study drug injection up to 21 days after last study drug injection (on-treatment analysis). Missing Week 12 data were imputed by last observation carried forward \[LOCF\] method.

Time frame:
Baseline to Week 12 (LOCF)
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis
percent changePlaceboAlirocumab 50 mg Q2WAlirocumab 100 mg Q2WAlirocumab 150 mg Q2WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4W
Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis-5.1 ± 3.1-39.6 ± 3.2-64.2 ± 3.1-72.4 ± 3.2-43.2 ± 3.3-47.7 ± 3.2
Statistical analysis
  • Placebo vs Alirocumab 150 mg Q2W · ANCOVA · p = <0.0001 (Threshold for significance ≤ 0.05.)
  • Placebo vs Alirocumab 300 mg Q4W · ANCOVA · p = <0.0001 (Threshold for significance ≤ 0.05.)
  • Placebo vs Alirocumab 100 mg Q2W · ANCOVA · p = <0.0001 (Threshold for significance ≤ 0.05.)
  • Placebo vs Alirocumab 200 mg Q4W · ANCOVA · p = <0.0001 (Threshold for significance ≤ 0.05.)
  • Placebo vs Alirocumab 50 mg Q2W · ANCOVA · p = <0.0001 (Threshold for significance ≤ 0.05.)
SecondaryAbsolute Change From Baseline in Calculated LDL-C (mmol/L) at Week 12 - On-Treatment Analysis

Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

Time frame:
Baseline to Week 12 (LOCF)
Reported as:
Least squares mean · mmol/L
Absolute Change From Baseline in Calculated LDL-C (mmol/L) at Week 12 - On-Treatment Analysis
mmol/LPlaceboAlirocumab 50 mg Q2WAlirocumab 100 mg Q2WAlirocumab 150 mg Q2WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4W
Absolute Change From Baseline in Calculated LDL-C (mmol/L) at Week 12 - On-Treatment Analysis-0.20 ± 0.10-1.37 ± 0.10-2.10 ± 0.10-2.38 ± 0.10-1.46 ± 0.11-1.62 ± 0.10
SecondaryAbsolute Change From Baseline in Calculated LDL-C (mg/dL) at Week 12 - On-Treatment Analysis

Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

Time frame:
Baseline to Week 12 (LOCF)
Reported as:
Least squares mean · mg/dL
Absolute Change From Baseline in Calculated LDL-C (mg/dL) at Week 12 - On-Treatment Analysis
mg/dLPlaceboAlirocumab 50 mg Q2WAlirocumab 100 mg Q2WAlirocumab 150 mg Q2WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4W
Absolute Change From Baseline in Calculated LDL-C (mg/dL) at Week 12 - On-Treatment Analysis-7.6 ± 3.9-53.0 ± 4.0-81.2 ± 3.9-92.0 ± 4.0-56.4 ± 4.1-62.5 ± 4.0
SecondaryPercentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) and <70 mg/dL (1.81 mmol/L) at Week 12 - On-Treatment Analysis
Time frame:
Week 12 (LOCF)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) and <70 mg/dL (1.81 mmol/L) at Week 12 - On-Treatment Analysis
percentage of participantsPlaceboAlirocumab 50 mg Q2WAlirocumab 100 mg Q2WAlirocumab 150 mg Q2WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4W
LDL-C <100 mg/dL (2.59 mmol/L)16.193.396.8100.089.396.7
LDL-C <70 mg/dL (1.81 mmol/L)3.246.783.9100.046.456.7
SecondaryPercent Change From Baseline in Total Cholesterol, High-density Lipoprotein Cholesterol (HDL-C), Non-HDL-C and Apolipoprotein B (Apo-B) at Week 12 - On-Treatment Analysis

Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

Time frame:
Baseline to Week 12 (LOCF)
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol, High-density Lipoprotein Cholesterol (HDL-C), Non-HDL-C and Apolipoprotein B (Apo-B) at Week 12 - On-Treatment Analysis
percent changePlaceboAlirocumab 50 mg Q2WAlirocumab 100 mg Q2WAlirocumab 150 mg Q2WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4W
Total Cholesterol (n= 31, 30, 31, 29, 28, 30)-1.6 ± 2.3-23.0 ± 2.3-39.7 ± 2.3-45.2 ± 2.3-28.0 ± 2.4-29.8 ± 2.3
HDL-C (n= 31, 30, 31, 29, 28, 30)-1.0 ± 2.36.7 ± 2.44.1 ± 2.35.5 ± 2.46.3 ± 2.58.5 ± 2.4
Non-HDL-C (n= 31, 30, 31, 29, 28, 30)-2.2 ± 2.9-33.6 ± 2.9-55.6 ± 2.9-62.5 ± 3.0-37.4 ± 3.0-40.7 ± 2.9
Apo-B (n= 30, 30, 30, 29, 27, 30)2.2 ± 2.9-27.3 ± 2.9-48.1 ± 2.9-56.1 ± 2.9-28.7 ± 3.1-33.1 ± 2.9
SecondaryPercent Change From Baseline in Fasting Triglycerides and Lipoprotein(a) at Week 12 - On-Treatment Analysis

Since the assumptions of normal distribution and equality of variances were not verified for the lipid parameters, percent changes were expressed as median (inter-quartile range).

Time frame:
Baseline to Week 12 (LOCF)
Reported as:
Median · percent change
Percent Change From Baseline in Fasting Triglycerides and Lipoprotein(a) at Week 12 - On-Treatment Analysis
percent changePlaceboAlirocumab 50 mg Q2WAlirocumab 100 mg Q2WAlirocumab 150 mg Q2WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4W
Fasting Triglycerides (n= 31, 30, 31, 29, 28, 30)9.7 (-15 to 30.7)-6.6 (-17.7 to 7.1)-5.5 (-22.1 to 10.7)-18.9 (-31.7 to -6.1)-10.8 (-25.4 to 13.3)-8.4 (-21.5 to 10.1)
Lipoprotein(a) (n= 30, 30, 30, 29, 27, 30)0.0 (-11.8 to 11.5)-13.3 (-33.3 to 0.0)-26.1 (-36.7 to -8.0)-28.6 (-46.9 to -22.2)-16.7 (-33.3 to -6.3)-7.9 (-18.8 to 0.0)
SecondaryAbsolute Change in the Ratio Apolipoprotein B/Apolipoprotein A-1 (ApoB/ApoA-1) From Baseline to Week 12 - On-Treatment Analysis

Adjusted LS mean and standard errors were estimated using the same ANCOVA as for primary endpoint.

Time frame:
Baseline to Week 12 (LOCF)
Reported as:
Least squares mean · ratio
Absolute Change in the Ratio Apolipoprotein B/Apolipoprotein A-1 (ApoB/ApoA-1) From Baseline to Week 12 - On-Treatment Analysis
ratioPlaceboAlirocumab 50 mg Q2WAlirocumab 100 mg Q2WAlirocumab 150 mg Q2WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4W
Absolute Change in the Ratio Apolipoprotein B/Apolipoprotein A-1 (ApoB/ApoA-1) From Baseline to Week 12 - On-Treatment Analysis0.05 ± 0.03-0.23 ± 0.03-0.35 ± 0.03-0.42 ± 0.03-0.23 ± 0.03-0.29 ± 0.03

Adverse events

Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 20) regardless of seriousness or relationship to investigational medicinal product (IMP).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/31 (3.2%)10/31 (32.3%)
Alirocumab 50 mg Q2W—0/30 (0%)14/30 (46.7%)
Alirocumab 100 mg Q2W—1/31 (3.2%)14/31 (45.2%)
Alirocumab 150 mg Q2W—0/31 (0%)12/31 (38.7%)
Alirocumab 200 mg Q4W—1/31 (3.2%)12/31 (38.7%)
Alirocumab 300 mg Q4W—1/28 (3.6%)10/28 (35.7%)
Most frequent serious events
Most frequent serious events
EventPlaceboAlirocumab 50 mg Q2WAlirocumab 100 mg Q2WAlirocumab 150 mg Q2WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4W
Leukocytoclastic vasculitisSkin and subcutaneous tissue disorders0/310/300/310/310/311/28
Humerus fractureInjury, poisoning and procedural complications0/310/300/310/310/311/28
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/310/301/310/310/310/28
ArthralgiaMusculoskeletal and connective tissue disorders0/310/300/310/311/310/28
Vertebral foraminal stenosisMusculoskeletal and connective tissue disorders1/310/300/310/310/310/28
Most frequent other events
Showing 10 of 24
Most frequent other events
EventPlaceboAlirocumab 50 mg Q2WAlirocumab 100 mg Q2WAlirocumab 150 mg Q2WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4W
NasopharyngitisInfections and infestations1/314/303/310/311/311/28
SinusitisInfections and infestations3/310/301/312/311/310/28
Injection site erythemaGeneral disorders0/310/303/313/311/311/28
Injection site pruritusGeneral disorders0/310/302/313/311/310/28
Urinary tract infectionInfections and infestations0/311/300/310/310/312/28
AnaemiaBlood and lymphatic system disorders0/311/300/310/310/312/28
DiarrhoeaGastrointestinal disorders0/310/301/311/311/312/28
ArthralgiaMusculoskeletal and connective tissue disorders1/310/301/311/310/312/28
Pain in extremityMusculoskeletal and connective tissue disorders1/310/300/310/312/312/28
FallInjury, poisoning and procedural complications0/310/300/311/311/312/28

Baseline characteristics

Randomized population.

Age, Continuous
Age, Continuous(years)PlaceboAlirocumab 50 mg Q2WAlirocumab 100 mg Q2WAlirocumab 150 mg Q2WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4WTotal
Mean53.3 ± 8.558.5 ± 9.158.1 ± 9.259.9 ± 11.154.9 ± 10.855.5 ± 10.156.7 ± 10.0
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAlirocumab 50 mg Q2WAlirocumab 100 mg Q2WAlirocumab 150 mg Q2WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4WTotal
Female15131821131696
Male16171310171487
Low-Density Lipoprotein Cholesterol (LDL-C) in mmol/L
Low-Density Lipoprotein Cholesterol (LDL-C) in mmol/L(mmol/L)PlaceboAlirocumab 50 mg Q2WAlirocumab 100 mg Q2WAlirocumab 150 mg Q2WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4WTotal
Mean3.4 ± 0.73.2 ± 0.73.3 ± 0.83.2 ± 0.73.3 ± 0.53.4 ± 0.63.3 ± 0.7
LDL-C in mg/dL
LDL-C in mg/dL(mg/dL)PlaceboAlirocumab 50 mg Q2WAlirocumab 100 mg Q2WAlirocumab 150 mg Q2WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4WTotal
Mean130.2 ± 27.3123.2 ± 27.9127.0 ± 30.4124.7 ± 26.9127.2 ± 19.6131.6 ± 24.8127.3 ± 26.2
08

Study locations

38 sites
  • Investigational Site Number 840525
    Tempe, Arizona 85282, United States
  • Investigational Site Number 840516
    Los Angeles, California 90057, United States
  • Investigational Site Number 840528
    Mission Viejo, California 92691, United States
  • Investigational Site Number 840509
    Newport Beach, California 92660, United States
  • Investigational Site Number 840523
    Palm Springs, California 92262, United States
  • Investigational Site Number 840534
    Westlake Village, California 91361, United States
  • Investigational Site Number 840530
    Colorado Springs, Colorado 80903, United States
  • Investigational Site Number 840504
    Aventura, Florida 33108, United States
  • Investigational Site Number 840519
    Aventura, Florida 33108, United States
  • Investigational Site Number 840514
    Jacksonville, Florida 32216, United States
  • Investigational Site Number 840539
    Jupiter, Florida 33458, United States
  • Investigational Site Number 840502
    Miami, Florida 33143, United States
  • Investigational Site Number 840520
    Pembroke Pines, Florida 33026, United States
  • Investigational Site Number 840524
    Ponte Vedra, Florida 32081, United States
  • Investigational Site Number 840536
    Port Orange, Florida 32127, United States
  • Investigational Site Number 840507
    St. Petersburg, Florida 33609, United States
  • Investigational Site Number 840527
    Chicago, Illinois 60611, United States
  • Investigational Site Number 840506
    Evansville, Indiana 47714, United States
  • Investigational Site Number 840529
    Indianapolis, Indiana 46260, United States
  • Investigational Site Number 840515
    Wichita, Kansas 67203, United States
  • Investigational Site Number 840532
    Madisonville, Kentucky 42431, United States
  • Investigational Site Number 840535
    Auburn, Maine 04210, United States
  • Investigational Site Number 840503
    Brockton, Massachusetts 02301, United States
  • Investigational Site Number 840512
    Las Vegas, Nevada 89123, United States
  • Investigational Site Number 840505
    Edison, New Jersey 08817, United States
  • Investigational Site Number 840538
    Rochester, New York 14609, United States
  • Investigational Site Number 840508
    Raleigh, North Carolina 27612, United States
  • Investigational Site Number 840522
    Statesville, North Carolina 28677, United States
  • Investigational Site Number 840511
    Cincinnati, Ohio 45219, United States
  • Investigational Site Number 840526
    Cincinnati, Ohio 45219, United States
  • Investigational Site Number 840510
    Lyndhurst, Ohio 44124, United States
  • Investigational Site Number 840533
    Tulsa, Oklahoma 74136, United States
  • Investigational Site Number 840537
    Eugene, Oregon 97404, United States
  • Investigational Site Number 840521
    Bristol, Tennessee 37620, United States
  • Investigational Site Number 840531
    Bountiful, Utah 84010, United States
  • Investigational Site Number 840517
    Norfolk, Virginia 23502, United States
  • Investigational Site Number 840518
    Richmond, Virginia 23227, United States
  • Investigational Site Number 840513
    Olympia, Washington 98502, United States
09

References and documents

Publications

  • McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012 Jun 19;59(25):2344-53. doi: 10.1016/j.jacc.2012.03.007. Epub 2012 Mar 28. PubMed 22463922 ↗
  • Gaudet D, Kereiakes DJ, McKenney JM, Roth EM, Hanotin C, Gipe D, Du Y, Ferrand AC, Ginsberg HN, Stein EA. Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). Am J Cardiol. 2014 Sep 1;114(5):711-5. doi: 10.1016/j.amjcard.2014.05.060. Epub 2014 Jun 18. PubMed 25060413 ↗
  • Leiter LA, Tinahones FJ, Karalis DG, Bujas-Bobanovic M, Letierce A, Mandel J, Samuel R, Jones PH. Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials. Diabet Med. 2018 Dec;35(12):1742-1751. doi: 10.1111/dme.13817. Epub 2018 Oct 9. PubMed 30183102 ↗
  • Toth PP, Hamon SC, Jones SR, Martin SS, Joshi PH, Kulkarni KR, Banerjee P, Hanotin C, Roth EM, McKenney JM. Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo. Lipids Health Dis. 2016 Feb 13;15:28. doi: 10.1186/s12944-016-0197-4. PubMed 26872608 ↗
  • Koren MJ, Kereiakes D, Pourfarzib R, Winegar D, Banerjee P, Hamon S, Hanotin C, McKenney JM. Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy. J Am Heart Assoc. 2015 Nov 19;4(11):e002224. doi: 10.1161/JAHA.115.002224. PubMed 26586732 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2015, 3 years 9 months after primary completion. A results delay was requested in Dec 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2011
First posted
Feb 2, 2011
Start
Jan 2011
Primary completionActual
Dec 2011
CompletionActual
Dec 2011
Results delay requested
Dec 12, 2012
Results first posted
Sep 24, 2015
Last update
Sep 24, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01288443
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Feb 2, 2011
Start date
Jan 2011
Primary completion
Dec 2011
Completion
Dec 2011
Results posted
Sep 24, 2015
Last update
Sep 24, 2015

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alirocumab

Start the discussion